Joshua J Kim

Mr. Joshua J Kim

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BBBrittany L. Bychkovsky
Brittany L. Bychkovsky
TLTianyu Li
Tianyu Li
JSJilliane Sotelo
Jilliane Sotelo
NTNabihah Tayob
Nabihah Tayob
JMJoanna Mercado
Joanna Mercado
NLNancy U.T. Lin
Nancy U.T. Lin
Purpose: Tumor-only genomic testing can uncover somatic and germline pathogenic variants [pathogenic/likely pathogenic (P/LP)] in cancer predisposition genes. We describe the prevalence of P/LPs in BRCA1/2 and PALB2 (B1B2P2) across malignancies and the frequency of clinical germline testing (CGT) in patients with P/LPs in B1B2P2 identified on tumor-only testing. Experimental Design: Among 7,575 patients with cancer tested between 2016 and 2018 with the OncoPanel tumor-only sequencing assay, we characterized P/LP frequencies by tumor type, receipt of CGT prior to or within 12 months after OncoPanel, and factors associated with CGT. Results: 272 (3.6%) patients had OncoPanel-detected P/LPs in B1B2P2: 37.5% of P/LPs were in BRCA-related cancers; the remainder were in non-BRCA tumors. P/LPs were detected in ≥5% of breast, pancreatic, prostate, ovarian, nonmelanoma skin, endometrial, small cell lung, and colorectal cancers. 37.9% of patients with P/LPs received CGT prior to OncoPanel; an additional 10.7% underwent CGT within 12 months of OncoPanel. Among 132 with CGT, 88.6% had ≥1 clinical factor for CGT compared with 47.1% who did not undergo CGT. Patients with BRCA tumors were more likely to have CGT compared with those without (81.4% vs. 29.0%, P < 0.0001). Among patients with CGT, 70.5% (93/132) of P/LPs were germline. Conclusions: Tumor-only genomic testing identified P/LPs in B1B2P2 in 3.6% of patients. 52.9% of patients with tumor-detected P/LPs and without CGT did not meet personal or family history criteria for CGT. In addition, some patients with tumor-detected P/LPs were not referred for CGT, especially those with non-BRCA tumors. Given implications for treatment selection and familial cancer risk, processes to reliably trigger CGT from tumor-genomic findings are needed.

5 June 2026 in Radiation
Verified
Journal Article
Open access
PDF file
LTLeila Tchelebi
Leila Tchelebi
JLJanice Lester
Janice Lester
JKJoshua J Kim
Joshua J Kim
HGHuaizhi Geng
Huaizhi Geng
YXYing Xiao
Ying Xiao
Radiation therapy quality assurance (RTQA) is critical to the success of RT and impacts trial outcomes. We aimed to evaluate the existence of standardized quantitative metrics to grade contours as part of RTQA and to identify barriers to standardization. A systematic review was conducted according to PRISMA guidelines. PubMed, Web of Science, and Embase were used to search relevant studies published from 2014–2024. Our endpoints were quantitative metrics used to guide contour scoring. We initially planned quantitative synthesis (meta-analysis) of geometric metric distributions across studies. However, the heterogeneity in evaluation methods, predominance of qualitative assessment, and lack of standardized reporting precluded meaningful quantitative pooling. We therefore performed structured qualitative synthesis, thematic analysis, and gap assessment. A total of 37 studies were included, 20 of which were prospective and 17 were retrospective. Of the prospective, 12 reported the results of benchmark case/dummy run reviews, 4 were a combination of benchmark case/dummy runs and individual QA analyses done pre- or post-treatment, 1 used knowledge-based planning to evaluate plans in real-time, and 3 involved real-time prospective QA. Only one reported the use of an objective QA scoring system. There is a concerning lack of standardized quantitative metrics to evaluate RT contours on clinical trials and a lack of methodological consistency required for systematic quantitative synthesis, reinforcing the need for standardization. Effort is needed to create guidelines for quantitatively evaluating RT contours to use across clinical trials to improve the quality and validity of RTQA.

31 March 2023
Verified
Other
Open access
BBBrittany L. Bychkovsky
Brittany L. Bychkovsky
TLTianyu Li
Tianyu Li
JSJilliane Sotelo
Jilliane Sotelo
NTNabihah Tayob
Nabihah Tayob
JMJoanna Mercado
Joanna Mercado
NLNancy U.T. Lin
Nancy U.T. Lin
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program

31 March 2023
Verified
Other
Open access
BBBrittany L. Bychkovsky
Brittany L. Bychkovsky
TLTianyu Li
Tianyu Li
JSJilliane Sotelo
Jilliane Sotelo
NTNabihah Tayob
Nabihah Tayob
JMJoanna Mercado
Joanna Mercado
NLNancy U.T. Lin
Nancy U.T. Lin
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program

31 March 2023
Verified
Other
Open access
BBBrittany L. Bychkovsky
Brittany L. Bychkovsky
TLTianyu Li
Tianyu Li
JSJilliane Sotelo
Jilliane Sotelo
NTNabihah Tayob
Nabihah Tayob
JMJoanna Mercado
Joanna Mercado
NLNancy U.T. Lin
Nancy U.T. Lin
Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program

31 March 2023
Verified
Other
Open access
BBBrittany L. Bychkovsky
Brittany L. Bychkovsky
TLTianyu Li
Tianyu Li
JSJilliane Sotelo
Jilliane Sotelo
NTNabihah Tayob
Nabihah Tayob
JMJoanna Mercado
Joanna Mercado
NLNancy U.T. Lin
Nancy U.T. Lin
Supplementary Figure from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program